95 related articles for article (PubMed ID: 7971509)
1. [Muromonab CD3--the first monoclonal antibody used in humans].
Makulska-Nowak E
Pol Tyg Lek; 1993 Dec 13-27; 48(50-52):857-9. PubMed ID: 7971509
[No Abstract] [Full Text] [Related]
2. Rationale for OKT3 monoclonal antibody treatment in transplant patients.
Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):1-3. PubMed ID: 8465414
[No Abstract] [Full Text] [Related]
3. Use of CD3 antibodies in transplantation and autoimmune diseases.
Chatenoud L
Transplant Proc; 1994 Dec; 26(6):3191-3. PubMed ID: 7998111
[No Abstract] [Full Text] [Related]
4. Monoclonal antibodies in organ transplantation.
Valdés RH
Transplant Proc; 1996 Dec; 28(6):3293. PubMed ID: 8962277
[No Abstract] [Full Text] [Related]
5. New usage paradigms in antibody therapy: safety of the new agents.
Pescovitz MD
Transplant Proc; 1999; 31(1-2):1201-2. PubMed ID: 10083537
[No Abstract] [Full Text] [Related]
6. Anti-CD3 antibodies.
Chatenoud L; Bach JF
Immunol Ser; 1993; 59():175-91. PubMed ID: 8461387
[No Abstract] [Full Text] [Related]
7. Therapeutic use of the monoclonal antibody Orthoclone OKT3.
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-58. PubMed ID: 3105133
[No Abstract] [Full Text] [Related]
8. Immunosuppressive effects of anti-CD3 MAb and soluble co-stimulatory molecules.
Bluestone JA; Bruce D; Peterson L; Thistlethwaite JR; Josephson M; Zeng Y; Linsley PS; Lenschow DJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):546-7. PubMed ID: 8438407
[No Abstract] [Full Text] [Related]
9. Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.
Kahan BD
Transplant Proc; 2009 Dec; 41(10):3975-4020. PubMed ID: 20005335
[No Abstract] [Full Text] [Related]
10. Minimizing the toxicity of antilymphocyte antibody therapy.
Pascual M; Rubin RH; Cosimi AB
Transplant Proc; 1996 Aug; 28(4):2113-4. PubMed ID: 8769171
[No Abstract] [Full Text] [Related]
11. Aseptic meningitis and muromonab-CD3 therapy.
Drees C; Haley CJ
DICP; 1991 Feb; 25(2):138-9. PubMed ID: 1905440
[No Abstract] [Full Text] [Related]
12. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
13. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
Bonnefoy-Berard N; Revillard JP
J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Basic Science Perspectives on the Use of OKT3. International symposium proceedings. Portland, Oregon, July 23-24, 1992.
Transplant Proc; 1993 Apr; 25(2 Suppl 1):1-93. PubMed ID: 8096662
[No Abstract] [Full Text] [Related]
15. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
16. Complications of using OKT3 for induction of immunosuppression in recipients of kidneys from nonheart beating donors.
Kehinde EO; Veitch PS; Scriven SD; Varty K; Morgan JD; Furness P; Horsburgh T; Feehally J; Bell PR
Transplant Proc; 1994 Dec; 26(6):3123-5. PubMed ID: 7998090
[No Abstract] [Full Text] [Related]
17. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP
Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548
[No Abstract] [Full Text] [Related]
18. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD3 antibody MacroGenics Inc.
Brown WM
Curr Opin Investig Drugs; 2006 Apr; 7(4):381-8. PubMed ID: 16625825
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity after treatment with muromonab-CD3.
Richards JM; Vogelzang NJ; Bluestone JA
N Engl J Med; 1990 Aug; 323(7):487-8. PubMed ID: 2115619
[No Abstract] [Full Text] [Related]
[Next] [New Search]
